In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International Murex Gets What It Wants

Executive Summary

The $234 million purchase of International Murex Technologies Corp. by Abbott Laboratories may seem like a pricey deal, but it isn't if one considers that the whole of Murex is worth more than the sum of its parts. Murex has no stellar technology, but rather a broad portfolio of niche tests in virology and infectious diseases. Abbott is interested in Murex' blood banking business, its rapid HIV diagnostic assay, its attractive patent portfolio, and its microtiter plate technology.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts